Add office photos
Employer?
Claim Account for FREE
Natco Pharma
4.0
based on 740 Reviews
Video summary
Company Overview
Company Locations
Working at Natco Pharma
Company Summary
An Indian pharmaceutical firm renowned for its production of oncology medications and hepatitis C treatments, strengthening healthcare access in the pharmaceutical sector.
Overall Rating
4.0/5
based on 740 reviews
3% above
industry average
Highly rated for
Job security, Salary, Work-life balance
Work Policy
Work from office
81% employees reported
Monday to Saturday
74% employees reported
Strict timing
53% employees reported
No travel
43% employees reported
View detailed work policy
Top Employees Benefits
Health insurance
50 employees reported
Job/Soft skill training
49 employees reported
Office cab/shuttle
24 employees reported
Cafeteria
22 employees reported
View all benefits
About Natco Pharma
Founded in1981 (44 yrs old)
India Employee Count1k-5k
Global Employee Count1k-5k
India HeadquartersHyderabad/Secunderabad, Telangana, India
Office Locations
--
Websitenatcopharma.co.in
Primary Industry
Other Industries
Are you managing Natco Pharma's employer brand? To edit company information,
claim this page for free
View in video summary
Natco Pharma is an Indian pharmaceutical company based in Hyderabad, which makes finished dosage formulations and active pharmaceutical ingredients. It is the market leader in branded oncology medicines in India, and among the country's top three in producing hepatitis C drugs.
Mission: Making specialty medicines accessible to all
Managing your company's employer brand?
Claim this Company Page for FREE
Natco Pharma Ratings
based on 740 reviews
Overall Rating
4.0/5
How AmbitionBox ratings work?
5
344
4
206
3
98
2
34
1
58
Category Ratings
3.9
Job security
3.8
Salary
3.8
Work-life balance
3.6
Skill development
3.6
Work satisfaction
3.5
Company culture
3.4
Promotions
Natco Pharma is rated 4.0 out of 5 stars on AmbitionBox, based on 740 company reviews. This rating reflects a generally positive employee experience, indicating satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Natco Pharma
based on 711 reviews
3.7
Rated by 56 Women
Rated 3.6 for Job security and 3.5 for Work-life balance
4.0
Rated by 655 Men
Rated 3.9 for Job security and 3.8 for Work-life balance
Work Policy at Natco Pharma
based on 94 reviews in last 6 months
Work from office
81%
Hybrid
16%
Permanent work from home
3%
Natco Pharma Reviews
Top mentions in Natco Pharma Reviews
+ 5 more
Compare Natco Pharma with Similar Companies
Change Company | Change Company | Change Company | ||
|---|---|---|---|---|
Overall Rating | 4.0/5 based on 740 reviews | 4.0/5 based on 5.8k reviews | 4.1/5 based on 6.9k reviews | 5.0/5 based on 1 reviews |
Highly Rated for | Job security Work-life balance Salary | Salary Skill development Job security | Skill development Salary Work-life balance | Skill development Work-life balance Salary |
Critically Rated for | No critically rated category | No critically rated category | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 81% employees reported | Work from office 82% employees reported | Work from office 72% employees reported | - |
Rating by Women Employees | 3.7 Good rated by 56 women | 4.0 Good rated by 441 women | 4.1 Good rated by 680 women | - no rating available |
Rating by Men Employees | 4.0 Good rated by 655 men | 4.0 Good rated by 5k men | 4.1 Good rated by 5.8k men | - no rating available |
Job security | 3.9 Good | 3.8 Good | 3.7 Good | 4.0 Good |
View more
Natco Pharma Salaries
Natco Pharma salaries have received with an average score of 3.8 out of 5 by 740 employees.
Officer
(269 salaries)
Unlock
₹2.2 L/yr - ₹8 L/yr
Assistant Officer
(134 salaries)
Unlock
₹1.8 L/yr - ₹6.1 L/yr
Deputy Manager
(108 salaries)
Unlock
₹9.6 L/yr - ₹16 L/yr
Business Development Executive
(84 salaries)
Unlock
₹2.8 L/yr - ₹6.2 L/yr
Chemist
(75 salaries)
Unlock
₹1.7 L/yr - ₹5.9 L/yr
Assistant Chemist
(52 salaries)
Unlock
₹1.8 L/yr - ₹4.1 L/yr
Area Business Manager
(45 salaries)
Unlock
₹5.9 L/yr - ₹11.2 L/yr
Senior Assistant
(44 salaries)
Unlock
₹2.2 L/yr - ₹6 L/yr
Medical Representative
(35 salaries)
Unlock
₹1.4 L/yr - ₹4.5 L/yr
Area Business Development Manager
(34 salaries)
Unlock
₹5.2 L/yr - ₹10.5 L/yr
Natco Pharma Interview Questions
Interview questions by designation
Top Natco Pharma interview questions and answers
Get interview-ready with top interview questions
Natco Pharma Jobs
Popular Designations Natco Pharma Hires for
Production
Create job alerts
Engineer
Create job alerts
Medical Representative
Create job alerts
Officer
Create job alerts
Executive
Create job alerts
Biologist
Create job alerts
Regulatory Affairs
Create job alerts
Analytical
Create job alerts
Natco Pharma News
View all
Trump US Tariffs Live Updates: Trade war escalates: Trump confirms 25% tariffs on Canada, Mexico, China responds
- Trump unveils new trade policy focused on fairness and reciprocity, implementing reciprocal tariffs on other countries.
- India faces risks due to its higher tariff rate and trade surplus with the US, potentially impacting exports.
- US import duties on steel and aluminum could affect Indian exports, but a bilateral trade deal may offer growth opportunities.
- Indian drugmakers and businesses prepare for potential impacts of US tariffs on their exports and operations.
- Natco Pharma seeks acquisitions in US and RoW markets to enhance its business presence and operations.
- Potential repercussions of 25% tariffs on semiconductors by the US for the global semiconductor industry are highlighted by IESA.
- Trump criticizes India's import tariffs, while Indian industries respond to potential reciprocal tariffs and trade implications.
- Goldman Sachs analysis suggests a potential 0.1% to 0.6% GDP growth reduction in light of Trump's proposed reciprocal tariffs on Indian imports.
- US auto tariffs minimally affect Indian car manufacturers but impact US companies sourcing auto components.
- Various industries in India, including farm exports and gold jewellery, anticipate challenges from proposed US reciprocal tariffs.
HinduBusinessLine | 4 Mar, 2025
HAL, Bharat Forge, NBCC, Gillette India Dividends: Last Day To Buy Shares To Qualify — Details Here
- HAL, Bharat Forge, NBCC, Gillette India will go ex-dividend soon.
- HAL announced an interim dividend of Rs 25 per equity share, while Bharat Forge will reward shareholders with an interim dividend of Rs 2.5.
- Other companies trading ex-dividend include Carborundum Universal, Greenpanel Industries, KPI Green Energy, and Natco Pharma.
- Investors need to buy shares by February 17 to be eligible for the dividend payments.
Bloomberg Quint | 17 Feb, 2025
Natco Pharma: Looming gap in earnings
- Natco Pharma reported a sharp decline in earnings, largely due to lower sales of generic Revlimid in the US.
- Under the sales agreement with the innovator, Natco Pharma and Teva are allowed to sell a predetermined market share, which affects revenue volatility.
- The company experienced strong sales growth in 9MFY25, but Q3 sales had no contribution from Revlimid.
- Natco Pharma faces a looming gap in earnings, but has stocked up on potential opportunities with new molecules for future growth.
HinduBusinessLine | 15 Feb, 2025
Natco Pharma Q3 Results Review: Dolat Capital Downgrades Both Rating, Target Price — Here's Why
- Dolat Capital downgrades Natco Pharma's rating to ‘Sell’ from Reduce with a revised target price of Rs 913 at 28 times FY27E P/E.
- Natco Pharma's exports declined by 52.8%/76.4% YoY/QoQ in Q3FY25 on account of absence of Revlimid sales during the quarter.
- Dolat Capital believes Natco is facing challenges in base business growth ex Revlimid as the ramp up across the segments is not in line with expectations, which has also led to significant erosion of core margins ex Revlimid.
- Dolat Capital downgrades both rating and target price due to the aforementioned challenges and lowered growth expectations.
Bloomberg Quint | 14 Feb, 2025
Q3 Results Highlights: Bharat Forge, Natco Pharma report Q3 profits; Ashok Leyland posts 34.63% rise
- Ashok Leyland reported a net profit of Rs 18.48 crore in the October-December period a year ago, with total income falling to Rs 179.87 crore in Q3 this fiscal, compared to Rs 240.57 crore year-on-year.
- Bharat Forge also posted a profit of Rs 608.85 crore in the third quarter last fiscal.
- Natco Pharma recorded a net profit of Rs 70.24 crore in the same period a year ago.
- Patel Engineering reported a consolidated net profit of ₹1391.5 crore in Q3 FY25 as against ₹1145.3 crore in the previous year's quarter.
- Steel Authority of India Ltd (SAIL) saw a 66.5% decline in net profit to ₹141.9 crore in the Q3 of December 2024, despite a 4.9% rise in revenue from operations.
- Lupin Limited's shares were trading at ₹2,062.15, down by ₹5.45 or 0.26% on the NSE.
- Alpex Solar, Knowledge Marine, Indo Tech Transformers, Khazanchi Jewellers, Ceinsys Tech, and One Point One all reported good to excellent results for Q3, with varying growth rates in sales and profits.
- Gensol, however, reported weak results for the quarter ending December 2024, with a decrease in net profit on a QoQ basis.
- The Navratna PSU's consolidated net profit fell 64.8% to ₹86.1 crore in Q3FY25 from ₹244.7 crore in the same period last year.
- Company's standalone net profit varied across different organizations, with some reporting profits and others losses in the quarter ended December 2024.
- Overall, the performance of various companies varied in Q3, with some showing growth and others facing challenges.
HinduBusinessLine | 12 Feb, 2025
Buy, Sell Or Hold: Zomato, RVNL, IRFC, Mankind Pharma, IOC, Bajaj Housing Finance — Ask Profit
- Analysts shared insights on share prices of Zen Technologies, Mankind Pharma, and Natco Pharma.
- RVNL (CMP: Rs 427.65) was advised to hold with strong support at Rs 410–415 levels.
- IRFC (CMP: Rs 141.73) was recommended to hold for one to two weeks with an upside target of 5–8% and a potential to reach Rs 155.
- Mankind Pharma (CMP: Rs 2,477.5) was suggested as a buy with a long-term target of Rs 2,700 in one year.
- Bajaj Housing Finance (CMP: Rs 1,115.87) was advised as a buy, as the numbers were good and there is a good upside potential.
- Zomato (CMP: Rs 222.50) was recommended as a sell, given the high volatility and overall downward trend in the stock.
- Natco Pharma (CMP: Rs 1,171.00) was advised to hold with a target of Rs 1,450 in six-eight months.
- Indian Oil Corp (CMP: Rs 123.64) was suggested to hold with a target of Rs 150–160 in six to 12 months.
- Zen Technologies (CMP: Rs 1,695.30) was recommended to hold for one to two years as a good pick in the long term.
Bloomberg Quint | 29 Jan, 2025
.jpg?w=1200&auto=format%2Ccompress&ogImage=true)
Natco Pharma Sells 14 Acres Of Land For Rs 116 Crore In Telangana
- Natco Pharma sold 14.38 acres of land in Telangana for Rs 116 crore.
- The sale of the land will not have any impact on the company's business operations.
- The details of the buyer were kept confidential as per an agreement between the two parties.
- Shares of Natco Pharma have gone ex-record dividend with the announced interim dividend of Rs 1.50 apiece.
Bloomberg Quint | 27 Nov, 2024
Natco Pharma Q2 Results Review - Strong Quarter, Pipeline Build-Up Underway: ICICI Securities
- ICICI Securities has reviewed Natco Pharma's Q2 results.
- They maintain a Hold rating on the stock with a target price of Rs 1,430.
- The brokerage highlights the strong quarter and pipeline build-up underway.
- They also mention limited competition opportunities in the U.S. market.
Bloomberg Quint | 14 Nov, 2024
Rare diseases patient representatives seek govt intervention to access treatment
- Rare diseases patient representatives are seeking government intervention to access treatment for conditions such as spinal muscular atrophy (SMA) and cystic fibrosis (CF).
- Roche, the maker of Risdiplam used to treat SMA, is seeking a permanent injunction against Natco Pharma from producing a generic version of the drug, hindering access to affordable options.
- Activists highlight the need for a coordinated treatment framework and express concerns about high drug costs and limited access in SMA cases.
- Cystic fibrosis patients in India face barriers due to patent restrictions, as the necessary drug has not been registered with Indian regulatory authorities.
HinduBusinessLine | 5 Nov, 2024
Movers & Shakers: Stocks that will see action this week
- Natco Pharma's stock is witnessing a corrective decline within the broader uptrend and bounced off the support at ₹1,290. It is anticipated to resume the uptrend and reach ₹1,700 in the coming months.
- The Ramco Cements stock has been gradually appreciating since July and is expected to breach ₹900, with a possible correction to ₹850. The outlook will turn negative if the stock falls below ₹800.
- Tata Power broke out of the range of ₹400-465 and the support at ₹400 remains valid. Buying interest is seen between ₹400 and ₹430, and the stock is expected to appreciate. Initial stop-loss is set at ₹360.
HinduBusinessLine | 2 Nov, 2024
Powered by
Natco Pharma Offices
Compare Natco Pharma with
Biocon Limited
3.9
Lupin
4.2
Zydus Lifesciences
4.1
Aurobindo Pharma
4.0
Glenmark Pharmaceuticals
3.9
Torrent Pharmaceuticals
3.9
DIVI'S Laboratories
3.7
Abbott
4.1
Granules India
3.8
Sanofi
4.2
Unichem Laboratories
3.8
Piramal Pharma
4.0
Strides Pharma
4.0
Jubilant Pharmova
3.8
Shilpa Medicare
3.4
Eris Lifesciences
3.7
Neuland Laboratories
4.1
NecLife
3.6
Medley Pharmaceuticals
4.0
Vasudha Pharma Chem
3.8
Edit your company information by claiming this page
Contribute & help others!
You can choose to be anonymous
Companies Similar to Natco Pharma
Sun Pharmaceutical Industries
Healthcare / Pharma, Manufacturing, Analytics & KPO, Pharma
4.0
• 5.8k reviews
DRJ & CO
Architecture & Interior Design
5.0
• 1 reviews
Cipla
Manufacturing, Pharma
4.1
• 6.9k reviews
Biocon Limited
Biotech & Life sciences, Biotechnology
3.9
• 1.9k reviews
Lupin
Biotech & Life sciences, Manufacturing, Pharma
4.2
• 6k reviews
Zydus Lifesciences
Biotech & Life sciences, Pharma
4.1
• 6k reviews
Aurobindo Pharma
Healthcare / Pharma, Biotechnology, Pharma
4.0
• 4.8k reviews
Glenmark Pharmaceuticals
Pharma
3.9
• 2.9k reviews
Torrent Pharmaceuticals
Pharma
3.9
• 2.5k reviews
DIVI'S Laboratories
Pharma
3.7
• 1.4k reviews
Abbott
Healthcare / Pharma, Media & Entertainment / Publishing, Pharma
4.1
• 3.1k reviews
Granules India
Manufacturing, Pharma
3.8
• 1.2k reviews
Natco Pharma FAQs
When was Natco Pharma founded?
Natco Pharma was founded in 1981. The company has been operating for 44 years primarily in the Pharma sector.
Where is the Natco Pharma headquarters located?
Natco Pharma is headquartered in Hyderabad/Secunderabad, Telangana.
How many employees does Natco Pharma have in India?
Natco Pharma currently has more than 4,900+ employees in India. Research & Development department appears to have the highest employee count in Natco Pharma based on the number of reviews submitted on AmbitionBox.
Does Natco Pharma have good work-life balance?
Natco Pharma has a Work-Life Balance Rating of 3.8 out of 5 based on 700+ employee reviews on AmbitionBox. 74% employees rated Natco Pharma 4 or above, while 26% employees rated it 3 or below on work-life balance. This indicates that the majority of employees feel a generally balanced work-life experience, with some opportunities for improvement based on the feedback. We encourage you to read Natco Pharma work-life balance reviews for more details
Is Natco Pharma good for career growth?
Career growth at Natco Pharma is rated as moderate, with a promotions and appraisal rating of 3.4. 26% employees rated Natco Pharma 3 or below, while 74% employees rated it 4 or above on promotions/appraisal. This rating suggests that while some employees view growth opportunities favorably, there is scope for improvement based on employee feedback. We recommend reading Natco Pharma promotions/appraisals reviews for more detailed insights.
What are the pros of working in Natco Pharma?
Working at Natco Pharma offers several advantages that make it an appealing place for employees. The company is highly rated for job security, salary & benefits and work life balance, based on 700+ employee reviews on AmbitionBox.
Stay ahead in your career. Get AmbitionBox app
Helping over 1 Crore job seekers every month in choosing their right fit company
75 Lakh+
Reviews
5 Lakh+
Interviews
4 Crore+
Salaries
1 Cr+
Users/Month
Contribute to help millions
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2024 Info Edge (India) Ltd.
Follow us
